Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints

Autores
Fushimi, Emilia; Rosales, Nicolás; De Battista, Hernán; Garelli, Fabricio
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Artificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart insulinpump with a Continuous Glucose Monitor (CGM) and a control algorithm to improve the regulation ofglycaemia. Based on the extensive clinical evidence provided by the main research groups in the area, ahybrid control algorithm combining insulin meal boluses and glucose feedback action has been recentlyapproved. However, this sort of algorithms should be refined especially during the postprandial period.In turn, fully closed-loop control strategies have to be further developed. In either case, intensive in vivovalidation is necessary to ensure the viability of the proposed strategy as an effective method to treatT1DM patients. In this paper, a safety layer called SAFE loop [1] is reformulated to be employed duringclinical trials in two different ways: the time enable mode to gradually activate the closed-loop controlafter an insulin meal bolus in hybrid configurations; and the amplitude enable mode to activate the fullclosed-loop control as long as the insulin infusion does not exceed the conventional therapy to a givenextent. The SAFE module decides the activation of the controller as a function of a constraint on the insulinon board (IOB). In the case of the Time Enable, this results in the use of a constant restriction on the IOB,whereas in the amplitude enable it results in the use of a time-varying IOB constraint. Both operationmodes are evaluated in silico using broadly accepted high-order models and the results contrasted withthe ones obtained without the SAFE protection.
Instituto de Investigaciones en Electrónica, Control y Procesamiento de Señales
Materia
Ingeniería Electrónica
Artificial pancreas
Clinical trial
Glucose control
Sliding mode control
Insulin-on-board
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/149290

id SEDICI_eaeca2412cc593f2d246d0384a835a2c
oai_identifier_str oai:sedici.unlp.edu.ar:10915/149290
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraintsFushimi, EmiliaRosales, NicolásDe Battista, HernánGarelli, FabricioIngeniería ElectrónicaArtificial pancreasClinical trialGlucose controlSliding mode controlInsulin-on-boardArtificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart insulinpump with a Continuous Glucose Monitor (CGM) and a control algorithm to improve the regulation ofglycaemia. Based on the extensive clinical evidence provided by the main research groups in the area, ahybrid control algorithm combining insulin meal boluses and glucose feedback action has been recentlyapproved. However, this sort of algorithms should be refined especially during the postprandial period.In turn, fully closed-loop control strategies have to be further developed. In either case, intensive in vivovalidation is necessary to ensure the viability of the proposed strategy as an effective method to treatT1DM patients. In this paper, a safety layer called SAFE loop [1] is reformulated to be employed duringclinical trials in two different ways: the time enable mode to gradually activate the closed-loop controlafter an insulin meal bolus in hybrid configurations; and the amplitude enable mode to activate the fullclosed-loop control as long as the insulin infusion does not exceed the conventional therapy to a givenextent. The SAFE module decides the activation of the controller as a function of a constraint on the insulinon board (IOB). In the case of the Time Enable, this results in the use of a constant restriction on the IOB,whereas in the amplitude enable it results in the use of a time-varying IOB constraint. Both operationmodes are evaluated in silico using broadly accepted high-order models and the results contrasted withthe ones obtained without the SAFE protection.Instituto de Investigaciones en Electrónica, Control y Procesamiento de Señales2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf1-9http://sedici.unlp.edu.ar/handle/10915/149290enginfo:eu-repo/semantics/altIdentifier/issn/1746-8094info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bspc.2018.05.009info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:38:16Zoai:sedici.unlp.edu.ar:10915/149290Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:38:17.213SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
title Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
spellingShingle Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
Fushimi, Emilia
Ingeniería Electrónica
Artificial pancreas
Clinical trial
Glucose control
Sliding mode control
Insulin-on-board
title_short Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
title_full Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
title_fullStr Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
title_full_unstemmed Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
title_sort Artificial pancreas clinical trials: Moving towards closed-loop control using insulin-on-board constraints
dc.creator.none.fl_str_mv Fushimi, Emilia
Rosales, Nicolás
De Battista, Hernán
Garelli, Fabricio
author Fushimi, Emilia
author_facet Fushimi, Emilia
Rosales, Nicolás
De Battista, Hernán
Garelli, Fabricio
author_role author
author2 Rosales, Nicolás
De Battista, Hernán
Garelli, Fabricio
author2_role author
author
author
dc.subject.none.fl_str_mv Ingeniería Electrónica
Artificial pancreas
Clinical trial
Glucose control
Sliding mode control
Insulin-on-board
topic Ingeniería Electrónica
Artificial pancreas
Clinical trial
Glucose control
Sliding mode control
Insulin-on-board
dc.description.none.fl_txt_mv Artificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart insulinpump with a Continuous Glucose Monitor (CGM) and a control algorithm to improve the regulation ofglycaemia. Based on the extensive clinical evidence provided by the main research groups in the area, ahybrid control algorithm combining insulin meal boluses and glucose feedback action has been recentlyapproved. However, this sort of algorithms should be refined especially during the postprandial period.In turn, fully closed-loop control strategies have to be further developed. In either case, intensive in vivovalidation is necessary to ensure the viability of the proposed strategy as an effective method to treatT1DM patients. In this paper, a safety layer called SAFE loop [1] is reformulated to be employed duringclinical trials in two different ways: the time enable mode to gradually activate the closed-loop controlafter an insulin meal bolus in hybrid configurations; and the amplitude enable mode to activate the fullclosed-loop control as long as the insulin infusion does not exceed the conventional therapy to a givenextent. The SAFE module decides the activation of the controller as a function of a constraint on the insulinon board (IOB). In the case of the Time Enable, this results in the use of a constant restriction on the IOB,whereas in the amplitude enable it results in the use of a time-varying IOB constraint. Both operationmodes are evaluated in silico using broadly accepted high-order models and the results contrasted withthe ones obtained without the SAFE protection.
Instituto de Investigaciones en Electrónica, Control y Procesamiento de Señales
description Artificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart insulinpump with a Continuous Glucose Monitor (CGM) and a control algorithm to improve the regulation ofglycaemia. Based on the extensive clinical evidence provided by the main research groups in the area, ahybrid control algorithm combining insulin meal boluses and glucose feedback action has been recentlyapproved. However, this sort of algorithms should be refined especially during the postprandial period.In turn, fully closed-loop control strategies have to be further developed. In either case, intensive in vivovalidation is necessary to ensure the viability of the proposed strategy as an effective method to treatT1DM patients. In this paper, a safety layer called SAFE loop [1] is reformulated to be employed duringclinical trials in two different ways: the time enable mode to gradually activate the closed-loop controlafter an insulin meal bolus in hybrid configurations; and the amplitude enable mode to activate the fullclosed-loop control as long as the insulin infusion does not exceed the conventional therapy to a givenextent. The SAFE module decides the activation of the controller as a function of a constraint on the insulinon board (IOB). In the case of the Time Enable, this results in the use of a constant restriction on the IOB,whereas in the amplitude enable it results in the use of a time-varying IOB constraint. Both operationmodes are evaluated in silico using broadly accepted high-order models and the results contrasted withthe ones obtained without the SAFE protection.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/149290
url http://sedici.unlp.edu.ar/handle/10915/149290
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1746-8094
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bspc.2018.05.009
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
1-9
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616258295693312
score 13.070432